5FA Stock Overview
Engages in the medical devices, pharmaceuticals, and pharma packaging businesses. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Nipro Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥8.15 |
| 52 Week High | JP¥8.60 |
| 52 Week Low | JP¥6.65 |
| Beta | 0.021 |
| 11 Month Change | 1.24% |
| 3 Month Change | 9.40% |
| 1 Year Change | 20.74% |
| 33 Year Change | -4.12% |
| 5 Year Change | n/a |
| Change since IPO | -15.10% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5FA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.5% | -2.5% | -1.3% |
| 1Y | 20.7% | -8.4% | 7.4% |
Return vs Industry: 5FA exceeded the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 5FA exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| 5FA volatility | |
|---|---|
| 5FA Average Weekly Movement | 2.7% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5FA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5FA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1947 | 38,117 | Yoshihiko Sano | www.nipro.co.jp |
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses. Its Medical-Related business develops, manufactures, and sells injection and infusion products, artificial organ products, functional products, dialysis products, diabetic products, and pharmaceuticals comprising generic and kit products; and manufactures medical equipment, including dialysis medical device products. This business also operates dialysis and training centers.
Nipro Corporation Fundamentals Summary
| 5FA fundamental statistics | |
|---|---|
| Market cap | €1.41b |
| Earnings (TTM) | €8.11m |
| Revenue (TTM) | €3.80b |
173.5x
P/E Ratio0.4x
P/S RatioIs 5FA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5FA income statement (TTM) | |
|---|---|
| Revenue | JP¥612.94b |
| Cost of Revenue | JP¥433.08b |
| Gross Profit | JP¥179.86b |
| Other Expenses | JP¥178.55b |
| Earnings | JP¥1.31b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.01 |
| Gross Margin | 29.34% |
| Net Profit Margin | 0.21% |
| Debt/Equity Ratio | 214.4% |
How did 5FA perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield337%
Payout RatioDoes 5FA pay a reliable dividends?
See 5FA dividend history and benchmarks| Nipro dividend dates | |
|---|---|
| Ex Dividend Date | Sep 27 2024 |
| Dividend Pay Date | Dec 09 2024 |
| Days until Ex dividend | 57 days |
| Days until Dividend pay date | 16 days |
Does 5FA pay a reliable dividends?
See 5FA dividend history and benchmarks